Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Santaris and miRagen Expand Partnership in the Field of Drugs Against microRNAs

Published: Wednesday, January 16, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
miRagen receives license to develop a further six LNA drugs.

Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and world-wide exclusive rights to research, develop and commercialize LNA drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need. This brings the total number of microRNA targets under the agreement to ten. Santaris Pharma A/S will receive a combination of cash and equity in consideration for the licenses as well as clinical milestones and royalties on products emerging from the alliance. Financial terms were not disclosed.

Henrik Ørum, CSO and VP, Business Development at Santaris Pharma A/S stated:  “Our collaboration with miRagen is an important part of our corporate strategy in the microRNA therapeutics field, so we are very pleased with our collective decision to expand the relationship. MicroRNA therapy is an exciting new branch of human medicine where the LNA drug platform has already provided proof-of-concept in phase2 clinical studies in HCV patient using Santaris´miRNA-122 inhibitor, Miravirsen.”

William S. Marshall, President and CEO of miRagen stated: “Our partnership with Santaris has been very productive, and we are excited to expand the relationship to additional microRNA targets in our portfolio. Our goal is to identify important disease causing microRNAs and to deploy the world’s best technologies to create therapeutic development candidates against diseases with high unmet medical need. We hope these new programs will translate into novel drugs that will help patients suffering from serious diseases live longer and better lives.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santaris Pharma Partners with Bristol-Myers Squibb
Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb to discover and develop novel RNA-targeted medicines.
Wednesday, April 24, 2013
LNA-based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Santaris Pharma’s EZN-2968 was well tolerated and showed clinical benefit in previously treated cancer patients with advanced malignancies.
Tuesday, June 16, 2009
Santaris Delivers Six LNA-Based RNA Inhibitors to Enzon Ahead of Schedule
Santaris announces completion of the delivery of six cancer target drug candidates to its collaboration partner Enzon.
Tuesday, April 28, 2009
Santaris Pharma Begins Human Clinical Testing of the World’s First Medicine Targeted at a Human microRNA
SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for Hepatitis C virus (HCV) infection.
Wednesday, May 28, 2008
Nature Publishes Study by Santaris Pharma Scientists and Collaborators
The paper demonstrates microRNA silencing in non-human primates, providing a validation of Santaris Pharma’s clinical program to develop a LNA-based therapeutics.
Friday, March 28, 2008
Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma
The Company’s collaboration partner Enzon Pharmaceuticals has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule.
Monday, November 05, 2007
Santaris Pharma Awarded €1.35M by Denmark’s Advanced Technology Foundation
Santaris Pharma has been awarded the grant towards the development of the first ever drug targeted against a human microRNA.
Wednesday, July 04, 2007
Santaris Pharma Raises EUR 40 M of new Equity
The funds will enable the further development of Santaris Pharma’s platform for LNA-based human therapeutics.
Friday, March 17, 2006
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!